ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets
ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets
Provider: View Press Release Type: Link Title: ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets | GSK Description: Findings show that cabotegravir LA for PrEP continued to demonstrate superior efficacy in the prevention of new HIV infections among women
GSK signs agreement to support pandemic preparedness in Europe
Provider: View Press Release Type: Link Title: GSK signs agreement to support pandemic preparedness in Europe | GSK Description: GSK will supply Adjupanrix to 12 participating European countries.
GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER, +13% at CER and Total EPS* from continuing operations** 17.5p -42% AER, -58% CER; Adjusted EPS of 34.7p +23% AER, +6% CER
GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER, +13% at CER and Total EPS* from continuing operations** 17.5p -42% AER, -58% CER; Adjusted EPS of 34.7p +23% AER, +6% CER
ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022
Provider: View Press Release Type: Link Title: ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022 | GSK Description: Data to be presented include long-term and real-world data from portfolio of medicines
Provider: View Press Release Type: Link Title: Completion of GSK Share Consolidation | GSK Description: The consolidation of GSK shares will become effective at 8.00 a.m. tomorrow
